MedPath

Beijing Zhifei Lvzhu Biopharmaceutical Co.,Ltd

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60

First Posted Date
2025-05-14
Last Posted Date
2025-05-18
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
60
Registration Number
NCT06970756
Locations
🇦🇺

Emeritus Research, Melbourne, Victoria, Australia

Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine

Phase 3
Not yet recruiting
Conditions
Dysentery
Dysentery, Shigella
Interventions
Biological: S. Flexneri-S. Sonnei bivalent conjugate vaccine
Biological: Placebo
First Posted Date
2025-02-20
Last Posted Date
2025-02-20
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
8000
Registration Number
NCT06838195
Locations
🇧🇩

Icddr,B, Dhaka, Bangladesh

Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine

Phase 3
Completed
Conditions
Streptococcus Pneumoniae Infections
Interventions
Biological: 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)
Biological: Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)
First Posted Date
2025-02-10
Last Posted Date
2025-02-10
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
1110
Registration Number
NCT06817187
Locations
🇨🇳

Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China

Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine

First Posted Date
2024-11-25
Last Posted Date
2025-01-27
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
450
Registration Number
NCT06703203
Locations
🇨🇳

Henan Provincial Center for Disease Control and Prevention, Shangqiu, Henan, China

Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old

Phase 1
Active, not recruiting
Conditions
Healthy Volunteers
Interventions
Biological: Inactivated rotavirus vaccine (low dose)
Biological: Inactivated rotavirus vaccine (high dose)
Biological: Placebo
First Posted Date
2024-04-05
Last Posted Date
2024-04-05
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
375
Registration Number
NCT06350058
Locations
🇨🇳

Hebei Provincial Center for Disease Control and Prevention, Shijiangzhuang, Hebei, China

Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants

Phase 3
Recruiting
Conditions
Healthy Volunteers
Interventions
Biological: Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)
Biological: Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine
Biological: Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)
First Posted Date
2024-04-03
Last Posted Date
2024-04-03
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
1584
Registration Number
NCT06344065
Locations
🇨🇳

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China

Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years

Phase 3
Active, not recruiting
Conditions
Healthy Population
Interventions
Biological: Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Biological: Group A and C Meningococcal Polysaccharide Vaccine
Biological: Group ACYW135 Meningococcal Polysaccharide Vaccine
First Posted Date
2024-03-18
Last Posted Date
2024-04-03
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
2450
Registration Number
NCT06314685
Locations
🇨🇳

Hunan Center for Disease Control and Prevention, Changsha, Hunan, China

Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months

Phase 3
Active, not recruiting
Conditions
Healthy Population
Interventions
Biological: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)
Biological: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)
Biological: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)
First Posted Date
2024-03-18
Last Posted Date
2024-04-03
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
630
Registration Number
NCT06314659
Locations
🇨🇳

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

Phase 1
Recruiting
Conditions
Healthy Volunteers
Interventions
Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
Biological: Placebo control
First Posted Date
2024-03-18
Last Posted Date
2024-04-03
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
300
Registration Number
NCT06314880
Locations
🇨🇳

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China

Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23

Phase 3
Active, not recruiting
Conditions
Healthy Volunteers
Interventions
Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)
Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)
Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)
First Posted Date
2024-03-18
Last Posted Date
2024-04-04
Lead Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Target Recruit Count
990
Registration Number
NCT06314867
Locations
🇨🇳

Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy